乳腺癌（BC）是一种常见的癌症，预后较差。本研究从癌症基因组图谱（TCGA）中获取了乳腺癌患者的mRNA和miRNA表达谱，使用生物信息学工具探索了一种新的乳腺癌患者预后策略。我们发现六个与糖酵解相关的miRNA（GRmiRs，包括hsa-mir-1247，hsa-mir148b，hsa-mir-133a-2，has-mir-1307，hsa-mir-195和hsa-mir-1258）与乳腺癌样本的预后相关。基于六个与预后相关的GRmiRs建立了风险评分模型。高风险组的预后结果明显较差。Cox回归分析显示风险评分是独立的预后因素。高风险组和低风险组之间鉴定出的差异表达基因主要富集在炎症和免疫相关信号通路中。高风险组和低风险组中12种免疫细胞的浸润比例明显不同。风险评分与许多免疫指标密切相关。多个差异表达基因和miRNA与药物相关。总之，糖酵解相关miRNA签名有效预测乳腺癌的预后。© 2023. 本文作者独家许可给Springer Science+Business Media, LLC，作为Springer Nature的一部分。

Breast cancer (BC) is a common type of cancer and has a poor prognosis. In this study, we collected the mRNA and miRNA expression profiles of BC patients were obtained from The Cancer Genome Atlas (TCGA) to explore a novel prognostic strategy for BC patients using bioinformatics tools. We found that six glycolysis-related miRNAs (GRmiRs, including hsa-mir-1247, hsa-mir148b, hsa-mir-133a-2, has-mir-1307, hsa-mir-195 and hsa-mir-1258) were correlated with prognosis of BC samples. The risk score model was established based on 6 prognosis-associated GRmiRs. The outcome of high risk group was significantly poorer. Cox regression analysis showed that risk score was an independent prognostic factor. Differentially expressed genes identified between high and low risk groups were mainly enriched in inflammation and immune-related signaling pathways. The proportion of infiltration of 12 kinds of immune cells in high and low risk groups were significantly different. Risk score was closely associated with many immune indexes. Multiple DEGRGs and miRNAs were associated with drugs. In conclusion, glycolysis-related miRNA signature effectively predicts BC prognosis.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.